461025-92-3

Upstream product

• 461025-91-2 1,2,3,6-tetra-O-benzoyl-4-deoxy-4-fluoro-α-D-glucopyranose 
• 114718-46-6 1,2,3,6-tetra-O-benzoyl-α-D-galactopyranose 
• 701936-21-2 4-deoxy-4-fluoro-1-O-acetyl-2,3,6-tri-O-benzoyl-D-glucopyranose 
• 702638-17-3 1-O-acetyl 2,3,6-tri-O-benzoyl-4-fluoro-4-deoxy-glucose 
• 1228019-06-4 1,2,3,6-tetra-O-benzoyl-β-D-galactopyranose 
• 59-23-4 D-Galactose 
• 98-88-4 benzoyl chloride 
• 93-97-0 benzoic acid anhydride 

Downstream Products

• 1233840-30-6 2-benzyl-4-[(4-methoxybenzyl)]-5-trifluoromethyl-pyrazol-3-yl-2,3,6-tri-O-benzoyl-4-deoxy-4-fluoro-β-D-glucopyranoside 
• 1025009-27-1 C₂₇H₂₂FN₃O₇ 
• 871484-01-4 C₄₀H₃₆BrFN₂O₈ 
• 461026-01-7 benzyl O-(4-deoxy-4-fluoro-β-D-glucopyranosiduronic acid)-(1->3)-2-acetamido-2-deoxy-β-D-galactopyranoside 
• 461026-00-6 benzyl O-(4-deoxy-4-fluoro-β-D-glucopyranosyl)-(1->3)-2-acetamido-2-deoxy-β-D-galactopyranoside 
• 461025-99-0 benzyl O-(2,3,6-tri-O-benzoyl-4-deoxy-4-fluoro-β-D-glucopyranosyl)-(1->3)-2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-tert-butyldimethylsilyl-β-D-galactopyranoside 

Relevant academic research and scientific papers

Process development of selectively benzoylated and fluorinated glycosyl donors

Route selection, process development and large-scale preparation of selectively benzoylated and fluorinated d-glucopyranoses, required as glycosyl donors for the synthesis of the SGLT inhibitor SAR7226, are discussed.

Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof

Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their p

NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF

The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I), in which the radicals have the indicated meanings, to the physiologically compatible salts thereof, and to a method for the production thereof. The compounds are suited for as, e.g. antidiabetics.

NOVEL FLUOROGLYCOSIDE HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL PRODUCTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF

The invention relates to substituted fluoroglycoside heterocyclic derivatives of a formula (I), wherein radicals have predefined bonds, to the psychologically tolerated salts thereof and to methods for the preparation thereof. Said compounds can be used, for example as antidiabetic agents.

Elucidation of the mechanism of polysaccharide cleavage by chondroitin AC lyase from Flavobacterium heparinum

Chondroitin AC lyase from Flavobacterium heparinum degrades chondroitin sulfate glycosaminoglycans via an elimination mechanism resulting in disaccharides or oligosaccharides with Δ4,5-unsaturated uronic acid residues at their nonreducing end. Mechanistic details concerning the ordering of the bond-breaking and -forming steps of this enzymatic reaction are nonexistent, mainly due to the inhomogeneous nature of the polymeric substrates. The creation of a new class of synthetic substrates for this enzyme has allowed the measurement of defined and reproducible kcat and Km values and has expanded the range of mechanistic studies that can be performed. The primary deuterium kinetic isotope effect upon kcat/Km for the abstraction of the proton α to the carboxylic acid was measured to be 1.67 ± 0.07, showing that deprotonation occurs in a rate-limiting step. Using substrates with leaving groups of differing reactivity, a flat linear free energy relationship was produced, indicating that the C4-O4 bond is not broken in a rate-determining step. Taken together, these results strongly suggest a stepwise mechanism. Consistent with this was the measurement of a secondary deuterium kinetic isotope effect upon kcat/Km of 1.01 ± 0.03 on a 4-{2H}-substrate, indicating that no sp2 character is developed at C4 during the rate-limiting step, thereby ruling out a concerted syn-elimination.